ALX Oncology Holdings Inc. (ALXO)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
0.92 USD
-0.06
(-6.110%) ⇩
(Oct. 14, 2026, 11:35 a.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 8:15 a.m. EDT
The investment case here is severely compromised by a catastrophic long-term price trajectory. Over the last five years, the stock has lost 95.4% of its value, a structural decline that suggests the market has permanently reassessed the company's viability despite recent clinical data. While the balance sheet currently shows a fortress-like liquidity position with a current ratio of 9.7 and manageable debt relative to cash, the relentless erosion of shareholder value over half a decade is a red flag that cannot be ignored. The business is burning cash, with negative free cash flow and poor returns on equity, and there is no dividend to provide any income cushion. On the short end, the technical picture is grim; the stock is trading well below its 50-day and 200-day moving averages, confirming a downtrend. Options activity reinforces this bearish sentiment, with traders buying protection rather than betting on a rally. Even though BlackRock increased its stake, this is likely passive accumulation typical of index funds, not a sign of active institutional conviction in a turnaround. The statistical forecasting model offers no help, showing very low confidence in any directional move. Until the multi-year decline is arrested and proven to be a temporary dislocation rather than a permanent failure, the outlook remains deeply negative. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.125367 |
| AutoARIMA | 0.125367 |
| MSTL | 0.128062 |
| AutoTheta | 0.172988 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 24% |
| H-stat | 45.42 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.005 |
| Excess Kurtosis | 0.00 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 8.105 |
| Market Cap | 127,145,696 |
| Forward P/E | -1.71 |
| Beta | 0.48 |
| Website | https://www.alxoncology.com |
As of Oct. 10, 2026, 8:15 a.m. EDT: Speculators are positioning defensively with heavy put volume at strikes below the current price ($1.50 and $2.00), while call interest remains sparse and concentrated far out-of-the-money. Implied volatility is extremely low across the board, indicating a lack of speculative fervor and a market consensus that significant upward moves are unlikely in the near term.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.40963858 |
| Address1 | 323 Allerton Avenue |
| All Time High | 117.45 |
| All Time Low | 0.404 |
| Ask | 1.31 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 1,357,460 |
| Average Daily Volume3 Month | 1,046,368 |
| Average Volume | 1,046,368 |
| Average Volume10Days | 1,357,460 |
| Beta | 0.476 |
| Bid | 0.9072 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 0.985 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.9195 |
| Current Ratio | 9.709 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 0.99 |
| Day Low | 0.89 |
| Debt To Equity | 8.105 |
| Display Name | ALX Oncology |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,778,243,400 |
| Earnings Call Timestamp Start | 1,778,243,400 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,968,200 |
| Earnings Timestamp Start | 1,793,968,200 |
| Ebitda | -82,295,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.1 |
| Enterprise Value | 8,265,146 |
| Eps Current Year | -2.64076 |
| Eps Forward | -0.53804 |
| Eps Trailing Twelve Months | -1.13 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.741 |
| Fifty Day Average Change | -0.82150006 |
| Fifty Day Average Change Percent | -0.47185528 |
| Fifty Two Week Change Percent | -40.96386 |
| Fifty Two Week High | 2.66 |
| Fifty Two Week High Change | -1.7405001 |
| Fifty Two Week High Change Percent | -0.65432334 |
| Fifty Two Week Low | 0.89 |
| Fifty Two Week Low Change | 0.029500008 |
| Fifty Two Week Low Change Percent | 0.033146076 |
| Fifty Two Week Range | 0.89 - 2.66 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,594,992,600,000 |
| Float Shares | 94,708,681 |
| Forward Eps | -0.53804 |
| Forward P E | -1.7089808 |
| Free Cashflow | -41,156,124 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 48 |
| Fullday Change | -0.06010002 |
| Fullday Change Percent | -6.1102095 |
| Fullday Price | 0.9195 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00892 |
| Held Percent Institutions | 0.84705 |
| Implied Shares Outstanding | 138,276,997 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California. |
| Long Name | ALX Oncology Holdings Inc. |
| Market | us_market |
| Market Cap | 127,145,696 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_301925264 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -80,890,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 200,501,645 |
| Number Of Analyst Opinions | 5 |
| Open | 0.99 |
| Operating Cashflow | -70,778,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Phone | 650 466 7125 |
| Previous Close | 0.9796 |
| Price Eps Current Year | -0.34819523 |
| Price Hint | 4 |
| Price To Book | 0.9335025 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.434 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.06010002 |
| Regular Market Change Percent | -6.1102095 |
| Regular Market Day High | 0.99 |
| Regular Market Day Low | 0.89 |
| Regular Market Day Range | 0.89 - 0.99 |
| Regular Market Open | 0.99 |
| Regular Market Previous Close | 0.9796 |
| Regular Market Price | 0.9195 |
| Regular Market Time | 1,791,992,149 |
| Regular Market Volume | 874,333 |
| Return On Assets | -0.40403 |
| Return On Equity | -0.80647004 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 138,276,997 |
| Shares Percent Shares Out | 0.040999997 |
| Shares Short | 5,673,137 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 7,064,802 |
| Short Name | ALX Oncology Holdings Inc. |
| Short Percent Of Float | 0.045500003 |
| Short Ratio | 4.97 |
| Source Interval | 15 |
| State | CA |
| Symbol | ALXO |
| Target High Price | 6.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 4.6 |
| Target Median Price | 4.0 |
| Total Cash | 138,228,992 |
| Total Cash Per Share | 1.0 |
| Total Debt | 11,038,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.13 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.8315 |
| Two Hundred Day Average Change | -0.91200006 |
| Two Hundred Day Average Change Percent | -0.49795252 |
| Type Disp | Equity |
| Volume | 874,333 |
| Website | https://www.alxoncology.com |
| Zip | 94,080 |